eFFECTOR Therapeutics, Inc. Common Stock
EFTR
EFTR was delisted on the 2nd of July, 2024.
26 hedge funds and large institutions have $9.94M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less capital invested
Capital invested by funds: $10.4M → $9.94M (-$483K)
13% less funds holding
Funds holding: 30 → 26 (-4)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$2.34M |
| 2 |
SOA
Sea Otter Advisors
Miami,
Florida
|
+$128K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$14.1K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$11.9K |
| 5 |
BlackRock
New York
|
+$8.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Corient Private Wealth
Miami,
Florida
|
-$118K |
| 2 |
Renaissance Technologies
New York
|
-$36.9K |
| 3 |
IDA
Intelligence Driven Advisers
Carlsbad,
California
|
-$24.4K |
| 4 |
Two Sigma Investments
New York
|
-$16.5K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$11.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $26 | – | – | – |
|
|
27
Corient Private Wealth
Miami,
Florida
| – | -$118K | -11,018 | Closed |
|
|
IDA
28
Intelligence Driven Advisers
Carlsbad,
California
| – | -$24.4K | -1,951 | Closed |
|
|
29
Two Sigma Investments
New York
| – | -$16.5K | -1,543 | Closed |
|
30
Millennium Management
New York
| – | -$9K | -844 | Closed |
|
31
Simplex Trading
Chicago,
Illinois
| – | -$3K | -344 | Closed |
|
32
Morgan Stanley
New York
| – | -$2.57K | -240 | Closed |
|
EFTR Hedge Fund Activity: Q1 2023 in Review
26 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q1 2023, worth a combined $9.94M — down 4.6% from $10.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of EFTR and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 3 added.
The largest buyer was Carlyle Group, opening a new position worth an estimated $2.34M. The largest seller was Corient Private Wealth, exiting entirely with an estimated $118K sold.
- 26 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q1 2023, down from 30 in Q4 2022.
- Funds reported $9.94M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q1 2023, down 4.6% quarter-over-quarter.
- 5 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q1 2023 and 6 closed out, a net change of -1 holder.
- The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q1 2023 was Carlyle Group, an estimated $2.34M added.
- The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q1 2023 was Corient Private Wealth, an estimated $118K sold.
Based on aggregated 13F filings for Q1 2023.